



EvaluatePharma®

Brazil Sales, Volume and Pricing

With ANVISA Approvals

Brazil Sales, Volume and Pricing

Gain competitive advantage with a comprehensive, timely and high quality source for Brazil sales, volume and pricing that includes hospital channels and reveals actual prices paid, mark-ups and government discounts.

Historically, it has been very difficult to access Brazil pharmaceutical pricing intelligence including reimbursed prices and discount information required to accurately assess the market.

Although available through government sites, Brazil pricing data is not user-friendly and is time consuming to analyse. For those requiring information in English, translation is required. Alternative ways to attain Brazil sales, volume and pricing market intelligence exist but involve using a combination of multiple data sources or by employing consultants. In addition, key data sets such as hospital channels and historic data may be unavailable.

Now through the EvaluatePharma platform, it is possible to analyse the Brazil market landscape by studying government sales, volume and pricing and ANVISA regulatory approvals in the global commercial context to make investment decisions, drive faster time-to-market, manage risks and optimise product performance.

Feature	Details
Comprehensive Government Sales	<ul style="list-style-type: none">• Aggregated, timely and fully transparent government contract (public sector) drug sales including hospital channels• Both Ministry of Health transparency portal and centralised procurement portal (Comprasnet), standardised and integrated for you• Includes volume & total sales
Government Discounts Clarity	<ul style="list-style-type: none">• Reimbursed guide price vs. government bid price and paid price, provided on a unit level
Brazil Pricing Intelligence	<ul style="list-style-type: none">• Three pricing levels: ex-factory; reimbursed and consumer• Annual and quarterly pricing in R\$ & US\$• Pack and derived unit prices• Ability to aggregate contract sales and rank by area of interest, E.g. company, product, therapy area
Integrated Historic Trends	<ul style="list-style-type: none">• Historic analysis 2005-2015
ANVISA Approvals Information	<ul style="list-style-type: none">• All approved products• Derived approval date and type from ANVISA approval codes• Search by therapy area, EphMRA code, indication• View orphan drugs and biosimilars• Filter by pack size, unit strength, dosing/formulation
International Reference Pricing	<ul style="list-style-type: none">• For US, Japan and key Western EU markets



Key Benefits:

- Standardised access to timely Brazil pricing intelligence in English with \$R and \$USD
- Fully integrated in the EvaluatePharma® service for in-depth global analysis
- Transparency into mark-ups, discounts and actual prices paid
- Includes hospital channel pricing and hospital drug sales that other sources lack



Corporate Strategists

Fully standardised and translated Brazil market insights reveal who the key players are and what products they are selling.



Business Development Teams

Commercial filters such as EphMRA code or indication facilitate rapid market sizing and aid identification of acquisition targets or partners.



Pricing and Reimbursement Teams

Sales, volume and pricing at pack and unit level enables easy direct comparisons to peer products in key markets such as USA, Japan, EU.



Population of over **200 million** people

2nd LARGEST

emerging market after China

Tenth largest Rx market worldwide*;

>US \$13 BILLION

LARGEST pharmaceutical market in **Latin America**



Requires careful evaluation and a targeted approach for which products to bring to market



*Source: The World Bank



Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support.

EvaluatePharma[®] delivers exclusive consensus sales forecasts and trusted commercial insight into biotech and pharmaceutical performance.

 [@EvaluatePharma](https://twitter.com/EvaluatePharma)

EvaluateMedTech[®] sets a new standard in commercial analysis and consensus forecasts of the global medical device and diagnostic industry.

 [@EvaluateMedTech](https://twitter.com/EvaluateMedTech)

EvaluateClinical Trials[®] delivers unique clinical trial intelligence expertly curated to efficiently analyse the global clinical trial landscape.

 [@EPClinicalTrial](https://twitter.com/EPClinicalTrial)

EP Vantage an award winning editorial team, provides daily commentary and analysis with fresh perspectives and insight into current and future industry trends.

 [@EPVantage](https://twitter.com/EPVantage)

Evaluate Custom Services provides customised solutions to help you access, analyse and manage the information you need to support effective decision-making.

The Evaluate services enable the life science community to make sound business decisions about value and opportunity.

www.evaluate.com

Evaluate Headquarters

Evaluate Ltd.
11-29 Fashion Street
London E1 6PX
United Kingdom
T +44 (0)20 7377 0800
F +44 (0)20 7539 1801

Evaluate Americas

EvaluatePharma USA Inc.
60 State Street, Suite 1910
Boston, MA 02109
USA
T +1 617 573 9450
F +1 617 573 9542

Evaluate Asia Pacific

Evaluate Japan KK
Akasaka Garden City 4F
4-15-1 Akasaka, Minato-ku
Tokyo 107-0052
Japan
T +81 (0)80 1164 4754